Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 2/2023

21-02-2023 | Human Immunodeficiency Virus

Update on Central Nervous System Effects of HIV in Adolescents and Young Adults

Authors: Jennifer L. McGuire, Judith B. Grinspan, Kelly L. Jordan-Sciutto

Published in: Current HIV/AIDS Reports | Issue 2/2023

Login to get access

Abstract

Purpose of Review.

Behaviorally acquired (non-perinatal) HIV infection during adolescence and young adulthood occurs in the midst of key brain developmental processes such as frontal lobe neuronal pruning and myelination of white matter, but we know little about the effects of new infection and therapy on the developing brain.

Recent Findings

Adolescents and young adults account for a disproportionately high fraction of new HIV infections each year. Limited data exist regarding neurocognitive performance in this age group, but suggest impairment is at least as prevalent as in older adults, despite lower viremia, higher CD4 + T cell counts, and shorter durations of infection in adolescents/young adults. Neuroimaging and neuropathologic studies specific to this population are underway.

Summary

The full impact of HIV on brain growth and development in youth with behaviorally acquired HIV has yet to be determined; it must be investigated further to develop future targeted treatment and mitigation strategies.
Literature
1.
2.
3.
4.••
Slogrove AL, Sohn AH. The global epidemiology of adolescents living with HIV. Curr Opin Hiv Aids. 2018;13:170–8. Excellent 2018 review of adolescents living with HIV and burden of HIV on their health and mortality.PubMedPubMedCentralCrossRef
5.
6.
7.
Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257–64.PubMedCrossRef
8.
9.
Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087–96.PubMedPubMedCentralCrossRef
10.
Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33–44.PubMedCrossRef
11.
Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol. 1997;54:416–24.PubMedCrossRef
12.
McGuire JL, Barrett JS, Vezina HE, et al. Adjuvant therapies for HIV-associated neurocognitive disorders. Ann Clin Transl Neurol. 2014;1(11):938–952.
13.
Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clinical Infectious. 2011;53:836–42.CrossRef
14.
Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010;75:1150–8.PubMedPubMedCentralCrossRef
15.
Carey CL, Woods SP, Rippeth JD, Gonzalez R, Moore DJ, Marcotte TD, Grant I, Heaton RK, Group H. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. The Clin Neuropsychologist. 2004;18:234–48.CrossRef
16.
Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26:759–78.PubMedCrossRef
17.
McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714.PubMed
18.•
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99. Summary of current HAND definitions and terminology.PubMedCrossRef
19.
Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16.PubMedCrossRef
20.
Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (London, England). 2009;23:1359–66.PubMedCrossRef
21.
Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol :The Official J Soc NeuroIm Pharmacol. 2010;5:294–309.CrossRef
22.
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (London, England). 2007;21:1915–21.PubMedCrossRef
23.
Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10:350–7.PubMedCrossRef
24.
Paul R, Cohen R, Navia B, Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev. 2002;26:353–9.PubMedCrossRef
25.
Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055–62.
26.
27.
Tan IL, McArthur JC. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs. 2012;26:123–34.PubMedCrossRef
28.
Grant I, Franklin DR, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82:2055–62.PubMedPubMedCentralCrossRef
29.
McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (London, England). 2010;24:1367–70.PubMedCrossRef
30.•
Johnson TP, Nath A. Biotypes of HIV-associated neurocognitive disorders based on viral and immune pathogenesis. Curr Opin Infect Dis. 2022;35:223–30. Proposal to subtype patients with HANDN into biotypes based on viral and immune pathogenesis.PubMedCrossRef
31.
Rubin LH, Ances BM. Working HAND in HAND: central nervous system complications in people with human immunodeficiency virus. Clin Infect Dis. 2021;74:1314–1314.CrossRef
32.••
Nichols SL, Bethel J, Garvie PA, Patton DE, Thornton S, Kapogiannis BG, Ren W, Major-Wilson H, Puga A, Woods SP. Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus. The J Adoles Health : Official Public Soc Adolesc Med. 2013;53:763–71. One of only two published studies that examine cognition in adolescents and young adults with behaviorally acquired HIV: This paper describes 220 18-24-year-old HIV+ youth enrolled in a prospective study evaluating strategies of antiretroviral (ART) treatment initiation and use, with an estimated HAND prevalence of 65%.CrossRef
33.••
Baker LM, Paul RH, Heaps JM, Westerhaus E, Chang JY, Williams S, Brier MR, Plax K, Ances BM. Impact of human immunodeficiency virus on neurocognition and risky behaviors in young adults. J Neurovirol. 2014;20:466–73. The second of two published studies that examine cognition in adolescents and young adults with behaviorally acquired HIV: This study is a case control study of 23 HIV+ and 21 HIV-youth aged 18–24 years, where over half of HIV+ subjects performed below expectation in an executive function task.PubMedPubMedCentralCrossRef
34.
Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011;204:753–60.PubMedPubMedCentralCrossRef
35.•
Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275–82. Excellent description of early HIV CNS invasion and related inflammation.PubMedPubMedCentralCrossRef
36.
Kolson DL. Neuropathogenesis of central nervous system HIV-1 infection. Clin Lab Med. 2002;22:703–17.PubMedCrossRef
37.
González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69–81.PubMedCrossRef
38.••
Angelovich TA, Churchill MJ, Wright EJ, Brew BJ. Neurocognitive complications of HIV-infection, neuropathogenesis to implications for clinical practice. Curr Top Behav Neurosci. 2020;50:3–39. Excellent overview of HIV neuropathogenesis and HAND.CrossRef
39.••
Farhadian S, Patel P, Spudich S. Neurological complications of HIV infection. Curr Infect Dis Rep. 2017;19:50. Very well written and complete overview of HIV neuropathogenesis, with a focus on recent important findings.PubMedPubMedCentralCrossRef
40.
McGuire JL, Goodkin K, Douglas SD. Neuropathogenesis of central nervous system HIV infection. Psychiatr Ann. 2013;43:212–6.CrossRef
41.
McGuire JL, Douglas SD. Neuroimmune dysregulation in HIV-associated neurocognitive disorders. Psychiatr Ann. 2013;43:217–22.CrossRef
42.
Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-Beck J, Navia B, Consortium HN. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63–9.PubMedPubMedCentralCrossRef
43.
Fischer-Smith T, Bell C, Croul S, Lewis M, Rappaport J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol. 2008;14:318–26.PubMedPubMedCentralCrossRef
44.•
Roth LM, Akay-Espinoza C, Grinspan JB, Jordan-Sciutto KL. HIV-induced neuroinflammation inhibits oligodendrocyte maturation via glutamate-dependent activation of the PERK arm of the integrated stress response. Glia. 2021;69:2252–71. Studies using an in vitro model of HIV infection, supernatant from HIV-infected macrophages, demonstrate that glutamate and other toxic products are released from infected macrophages and inhibit oligodendrocyte differentiation in vitro, at least partially via the integrated stress response.PubMedPubMedCentralCrossRef
45.
Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, Alvarez X, Kuroda MJ, Williams KC. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog. 2010;6:e1000842.PubMedPubMedCentralCrossRef
46.
Tang X, Lu H, Ramratnam B. Neurotoxicity of HIV-1 Tat is attributed to its penetrating property. Sci Rep-uk. 2020;10:14002.CrossRef
47.
Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci. 2007;27:3703–11.PubMedPubMedCentralCrossRef
48.
Ulfhammer G, Edén A, Mellgren Å, Fuchs D, Zetterberg H, Hagberg L, Nilsson S, Yilmaz A, Gisslén M. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS. 2018;32:2171–8.PubMedCrossRef
49.
Krut JJ, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, Nilsson S, Zetterberg H, Gisslen M. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS ONE. 2014;9:e88591.CrossRef
50.
Rubin LH, Sacktor N, Creighton J, Du Y, Endres CJ, Pomper MG, Coughlin JM. Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy. AIDS. 2018;32:1661–7.PubMedCrossRef
51.
Rubin LH, Maki PM, Springer G, et al. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. Neurology. 2017;89:1594–603.PubMedPubMedCentralCrossRef
52.
Paul RH, Ernst T, Brickman AM, Yiannoutsos CT, Tate DF, Cohen RA, Navia BA, ACTG 301 team; ACTG 700 team; HIV MRS consortium. relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsych Soc. 2008;14:725–33.CrossRef
53.
Ances BM, Ortega M, Vaida F, Heaps J. Paul R (2012) Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 1999;59:469–77.CrossRef
54.
Küper M, Rabe K, Esser S, Gizewski ER, Husstedt IW, Maschke M, Obermann M. Structural gray and white matter changes in patients with HIV. J Neurol. 2011;258:1066–75.PubMedCrossRef
55.
Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M, Ernst T. Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits. Neurology. 2014;82:2213–22.PubMedPubMedCentralCrossRef
56.
Archibald SL, Masliah E, Fennema-Notestine C, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol. 2004;61:369–76.PubMedCrossRef
57.••
Gelman BB. Neuropathology of HAND with suppressive antiretroviral therapy: encephalitis and neurodegeneration reconsidered. Curr HIV/AIDS Rep. 2015;12:272–9. Thoughtful examination of HIV neuropathophysiology in the context of cART.PubMedPubMedCentralCrossRef
58.
Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topics in antiviral medicine. 2011;19:137–42.PubMed
59.
Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol. 1997;42:963–72.PubMedCrossRef
60.
Gelman BB, Lisinicchia JG, Morgello S, et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr. 2013;62(5):487–95.PubMedPubMedCentralCrossRef
61.
Hoare J, Fouche J-P, Spottiswoode B, Joska JA, Schoeman R, Stein DJ, Carey PD. White matter correlates of apathy in HIV-positive subjects: a diffusion tensor imaging study. J Neuropsychiatry Clin Neurosci. 2010;22:313–20.PubMedCrossRef
62.
Gongvatana A, Cohen RA, Correia S, Devlin KN, Miles J, Kang H, Ombao H, Navia B, Laidlaw DH, Tashima KT. Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol. 2011;17:477–86.PubMedPubMedCentralCrossRef
63.
Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathology (Zurich, Switzerland). 2003;13:195–210.PubMedCrossRef
64.
Müller-Oehring EM, Schulte T, Rosenbloom MJ, Pfefferbaum A, Sullivan EV. Callosal degradation in HIV-1 infection predicts hierarchical perception: a DTI study. Neuropsychologia. 2010;48:1133–43.PubMedCrossRef
65.
Rostasy K, Monti L, Yiannoutsos C, Kneissl M, Bell J, Kemper TL, Hedreen JC, Navia BA. Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. Ann Neurol. 1999;46:207–16.PubMedCrossRef
66.
Rostásy KM. Inflammation and neuroaxonal injury in multiple sclerosis and AIDS dementia complex: implications for neuroprotective treatment. Neuropediatrics. 2005;36:230–9.PubMedCrossRef
67.
Solomon IH, Chettimada S, Misra V, Lorenz DR, Gorelick RJ, Gelman BB, Morgello S, Gabuzda D. White matter abnormalities linked to interferon, stress response, and energy metabolism gene expression changes in older HIV-positive patients on antiretroviral therapy. Mol Neurobiol. 2020;57:1115–30.PubMedCrossRef
68.
Levine AJ, Soontornniyomkij V, Achim CL, Masliah E, Gelman BB, Sinsheimer JS, Singer EJ, Moore DJ. Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. J Neurovirol. 2016;22:431–41.PubMedCrossRef
69.
Miller RF, Lucas SB, Hall-Craggs MA, Brink NS, Scaravilli F, Chinn RJ, Kendall BE, Williams IG, Harrison MJ. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. J Neurol Neurosurg Psychiatry. 1997;62:346–51.PubMedPubMedCentralCrossRef
70.
Everall IP, Chong WK, Wilkinson ID, Paley MN, Chinn RJ, Hall-Craggs MA, Scaravilli F, Lantos PL, Luthert PJ, Harrison MJ. Correlation of MRI and neuropathology in AIDS. J Neurol Neurosurg Psychiatry. 1997;62:92–5.PubMedPubMedCentralCrossRef
71.
Grafe MR, Press GA, Berthoty DP, Hesselink JR, Wiley CA. Abnormalities of the brain in AIDS patients: correlation of postmortem MR findings with neuropathology. AJNR Am J neuroradiol. 1990;11:905–11 (discussion 912-3).PubMedPubMedCentral
72.
McGuire J, Brown R, Datta R, Fadda G, Tuite N, Harrison J, Douglas S, Banwell B. Impaired cognition and reduced brain volumes in youth with behaviorally acquired HIV. in: Conference on Retroviruses and Opportunistic Infections (CROI); presented 3/8/20; Boston MA.
73.•
Douglas SD, Rudy B, Muenz L, Starr SE, Campbell DE, Wilson C, Holland C, Crowley-Nowick P, Vermund SH. T-lymphocyte subsets in HIV-infected and high-risk HIV-uninfected adolescents: retention of naive T lymphocytes in HIV-infected adolescents. The Adolescent Medicine HIV/AIDS Research Network. Arch Pediatr Adolesc Med. 2000;154:375–80. Core paper in discussing differing immunologic responses in adolescents with behaviorally acquired HIV compared to expected responses in adults.PubMedCrossRef
74.
75.
Lenroot RK, Giedd JN. Brain development in children and adolescents: insights from anatomical magnetic resonance imaging. Neurosci Biobehav Rev. 2006;30:718–29.PubMedCrossRef
76.
Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, Evans AC, Rapoport JL. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999;2:861–3.PubMedCrossRef
77.
Berl MM, Vaidya CJ, Gaillard WD. Functional imaging of developmental and adaptive changes in neurocognition. Neuroimage. 2006;30:679–91.PubMedCrossRef
78.
79.•
McGuire JL, Gill AJ, Douglas SD, Kolson DL, CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group. The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth. Journal of Neurovirology. 2016;22:823–30. ()PubMedPubMedCentralCrossRef
80.
Jensen BK, Monnerie H, Mannell MV, et al. Altered oligodendrocyte maturation and myelin maintenance: the role of antiretrovirals in HIV-associated neurocognitive disorders. J Neuropathol Exp Neurol. 2015;74:1093–118.PubMedCrossRef
81.•
Jensen BK, Roth LM, Grinspan JB, Jordan-Sciutto KL. White matter loss and oligodendrocyte dysfunction in HIV: a consequence of the infection, the antiretroviral therapy or both? Brain Res. 2019;1724: 146397. Review of evidence of myelin pathology from human HIV studies and review of studies on oligodendrocyte development and maintenance in vitro and in animal models in the presence of viral proteins or antiretroviral drugs.PubMedPubMedCentralCrossRef
82.
Douglas SD, Durako SJ, Tustin NB, Houser J, Muenz L, Starr SE, Wilson C, Network AMHAR. Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses. 2001;17:543–52.PubMedCrossRef
83.
Norris GT, Smirnov I, Filiano AJ, Shadowen HM, Cody KR, Thompson JA, Harris TH, Gaultier A, Overall CC, Kipnis J. Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury. J Exp Med. 2018;215:1789–801.PubMedPubMedCentralCrossRef
84.••
Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–78. Seminal work on the role of the complement cascade in microglial mediated pruning.PubMedCrossRef
85.
Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.PubMedCrossRef
86.
Alexander JJ, Anderson AJ, Barnum SR, Stevens B, Tenner AJ. The complement cascade: Yin-Yang in neuroinflammation–neuro-protection and -degeneration. J Neurochem. 2008;107:1169–87. [abstract]
87.
Everall I, Heaton R, Marcotte T, Ellis R, McCutchan J, Atkinson J, Grant I, Mallory M, Masliah E, Group H. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol. 1999;9:209–17.PubMedCrossRef
88.
Ryan SK, Gonzalez MV, Garifallou JP, et al. Neuroinflammation and EIF2 signaling persist despite antiretroviral treatment in an hiPSC tri-culture model of HIV infection. Stem Cell Rep. 2020;14:703–16.CrossRef
89.
Mazzolini J, Herit F, Bouchet J, Benmerah A, Benichou S, Niedergang F. Inhibition of phagocytosis in HIV-1-infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments. Blood. 2010;115:4226–36.PubMedCrossRef
90.
Debaisieux S, Lachambre S, Gross A, Mettling C, Besteiro S, Yezid H, Henaff D, Chopard C, Mesnard J-M, Beaumelle B. HIV-1 Tat inhibits phagocytosis by preventing the recruitment of Cdc42 to the phagocytic cup. Nat Commun. 2015;6:6211.PubMedCrossRef
91.
Chari DM, Blakemore WF. Efficient recolonisation of progenitor-depleted areas of the CNS by adult oligodendrocyte progenitor cells. Glia. 2002;37:307–13.PubMedCrossRef
92.
Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New Engl J Medicine. 2002;346:165–73.CrossRef
93.
Hughes EG, Orthmann-Murphy JL, Langseth AJ, Bergles DE. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat Neurosci. 2018;21:696–706.PubMedPubMedCentralCrossRef
94.
Bechler ME, Swire M, ffrench-Constant C. Intrinsic and adaptive myelination—a sequential mechanism for smart wiring in the brain. Dev Neurobiol. 2018;78:68–79.PubMedCrossRef
95.
Borjabad A, Morgello S, Chao W, Kim S-Y, Brooks AI, Murray J, Potash MJ, Volsky DJ. Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. Plos Pathog. 2011;7:e1002213.PubMedPubMedCentralCrossRef
96.
Gannon PJ, Akay-Espinoza C, Yee AC, et al. HIV protease inhibitors alter amyloid precursor protein processing via β-site amyloid precursor protein cleaving enzyme-1 translational up-regulation. Am J Pathology. 2017;187:91–109.CrossRef
97.
Stern AL, Lee RN, Panvelker N, Li J, Harowitz J, Jordan-Sciutto KL, Akay-Espinoza C. Differential effects of antiretroviral drugs on neurons in vitro: roles for oxidative stress and integrated stress response. J Neuroimmune Pharm. 2018;13:64–76.CrossRef
98.
99.
100.
Monnerie H, Romer M, Jensen BK, Millar JS, Jordan-Sciutto KL, Kim SF, Grinspan JB. Reduced sterol regulatory element-binding protein (SREBP) processing through site-1 protease (S1P) inhibition alters oligodendrocyte differentiation in vitro. J Neurochem. 2017;140:53–67.PubMedCrossRef
101.
Kavanaugh B, Beesley J, Itoh T, Itoh A, Grinspan J, Pleasure D. Neurotrophin-3 (NT-3) diminishes susceptibility of the oligodendroglial lineage to AMPA glutamate receptor-mediated excitotoxicity. J Neurosci Res. 2000;60:725–32.PubMedCrossRef
102.
Akay C, Cooper M, Odeleye A, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol. 2014;20:39–53.PubMedPubMedCentralCrossRef
103.
Akay C, Lindl KA, Shyam N, Nabet B, Goenaga-Vazquez Y, Ruzbarsky J, Wang Y, Kolson DL, Jordan-Sciutto KL. Activation status of integrated stress response pathways in neurones and astrocytes of HIV-associated neurocognitive disorders (HAND) cortex: activation of integrated stress response in HAND. Neuropath Appl Neuro. 2012;38:175–200.CrossRef
104.
Lindl KA, Akay C, Wang Y, White MG, Jordan-Sciutto KL. Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropath Appl Neuro. 2007;33:658–69.CrossRef
105.•
Festa L, Roth LM, Jensen BK, Geiger JD, Jordan-Sciutto KL, Grinspan JB. Protease inhibitors, saquinavir and darunavir, inhibit oligodendrocyte maturation: implications for lysosomal stress. J Neuroimmune Pharm. 2021;16:169–80. Oligodendrocyte development is inhibited in vitro by two frontline protease inhibitors. Lysosomal deacidification is implicated and differentiation can be rescued by lysosomal reacidification.CrossRef
106.••
Roth LM, Zidane B, Festa L, Putatunda R, Romer M, Monnerie H, Jordan-Sciutto KL, Grinspan JB. Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: a role for the integrated stress response. Glia. 2021;69:362–76. The integrase strand transfer inhibitor, elvitegravir, inhibits oligodendrocyte maturation in vitro via the integrated stress response, whereas another INSTI, raltegravir, has no effect on maturation. Elivategravir also inhibits demyelination in vivo in an animal model of demyelination.PubMedCrossRef
107.
Gelman B, Morgello S. National NeuroAIDS Tissue Bank, personal communication. 2015.
108.
Mallard J, Williams KC. Animal models of HIV-associated disease of the central nervous system. Handb Clin Neurology. 2018;152:41–53.CrossRef
109.••
Joseph J. Optimizing animal models for HIV-associated CNS dysfunction and CNS reservoir research. J Neurovirol. 2018;24:137–40. Comprehensive summary of existing animal models used to study HIV-associated CNS dysfunction.PubMedCrossRef
110.
Zehr JL, van Meter PE, Wallen K. Factors regulating the timing of puberty onset in female rhesus monkeys (Macaca mulatta): role of prenatal androgens, social rank, and adolescent body weight. Biol Reprod. 2005;72:1087–94.PubMedCrossRef
111.
Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc National Acad Sci. 2001;98:9271–6.CrossRef
112.
Repunte-Canonigo V, Lefebvre C, George O, Kawamura T, Morales M, Koob GF, Califano A, Masliah E, Sanna PP. Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener. 2014;9:26–26.PubMedPubMedCentralCrossRef
113.
Lentz MR, Peterson KL, Ibrahim WG, Lee DE, Sarlls J, Lizak MJ, Maric D, Reid WC, Hammoud DA. Diffusion tensor and volumetric magnetic resonance measures as biomarkers of brain damage in a small animal model of HIV. PLoS ONE. 2014;9:e105752.PubMedPubMedCentralCrossRef
114.
Mayer KH, Molina J-M, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239–54.PubMedPubMedCentralCrossRef
115.
Li MD, Cao J, Wang S, Wang J, Sarkar S, Vigorito M, Ma JZ, Chang SL. Transcriptome sequencing of gene expression in the brain of the HIV-1 transgenic rat. PLoS ONE. 2013;8:e59582.PubMedPubMedCentralCrossRef
Metadata
Title
Update on Central Nervous System Effects of HIV in Adolescents and Young Adults
Authors
Jennifer L. McGuire
Judith B. Grinspan
Kelly L. Jordan-Sciutto
Publication date
21-02-2023
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 2/2023
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-023-00651-3

Other articles of this Issue 2/2023

Current HIV/AIDS Reports 2/2023 Go to the issue

ReviewPaper

The Gut Microbiome, Microbial Metabolites, and Cardiovascular Disease in People Living with HIV

ReviewPaper

Updates on HIV and Kidney Disease

ReviewPaper

Advances in HIV Research Using Mass Cytometry

ReviewPaper

HIV Reservoir: How to Measure It?

ReviewPaper

Sustaining HIV Research in Resource-Limited Settings Using PLAN (People, Learning, Adapting, Nurturing): Evidence from the 4 Youth by Youth Project in Nigeria

ReviewPaper

Biological Aging in People Living with HIV on Successful Antiretroviral Therapy: Do They Age Faster?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits